Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.35 |
| ▸ | DHPS | P49366 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2993853 | 0.92 | BACE1 (0.31) | BACE1 | |
| SCHEMBL3004858 | 0.89 | KMT2A (0.35) | ITGB3ITGA2BDHPSBACE1 | |
| SCHEMBL2998693 | 0.80 | KMT2A (0.36) | BACE1 | |
| SCHEMBL2997716 | 0.80 | ITGB3 (0.36) | ITGB3ITGA2BDHPS | |
| SCHEMBL3006179 | 0.80 | ITGB3 (0.38) | ITGB3ITGA2BDHPS | |
| SCHEMBL3002199 | 0.80 | ITGB3 (0.38) | ITGB3ITGA2BDHPS | |
| SCHEMBL3005862 | 0.79 | ITGB3 (0.37) | ITGB3ITGA2BDHPSBACE1 | |
| SCHEMBL3653143 | 0.79 | ITGB3 (0.37) | ITGB3ITGA2BDHPS | |
| SCHEMBL2996231 | 0.74 | DHPS (0.42) | ITGB3ITGA2BDHPS | |
| SCHEMBL2998670 | 0.71 | DHPS (0.40) | ITGB3ITGA2BDHPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372864-B2 | 1-oxo-isoindoline-4-carboxamide and 1-oxo-1,2,3,4-tetrahydroisoquinoline-5-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-02-12 | — | — | US | disclosed |
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-2185511-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009044019-A2 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197725-A1 | 1-OXO-ISOINDOLINE-4-CARBOXAMIDE AND 1-OXO-1,2,3,4-TETRAHYDROISOQUINOLINE-5-CARBOXAMIDE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | COX4I1, CNR2, CNR1 | ITGB3 3447/4885ITGA2B 3449/4885DHPS 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.